GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » Beneish M-Score

FRTX (Fresh Tracks Therapeutics) Beneish M-Score : -4.26 (As of Dec. 11, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Fresh Tracks Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.26 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Fresh Tracks Therapeutics's Beneish M-Score or its related term are showing as below:

FRTX' s Beneish M-Score Range Over the Past 10 Years
Min: -4.26   Med: -2.75   Max: -1.14
Current: -4.26

During the past 13 years, the highest Beneish M-Score of Fresh Tracks Therapeutics was -1.14. The lowest was -4.26. And the median was -2.75.


Fresh Tracks Therapeutics Beneish M-Score Historical Data

The historical data trend for Fresh Tracks Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh Tracks Therapeutics Beneish M-Score Chart

Fresh Tracks Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.14 - - - -4.26

Fresh Tracks Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -5.34 -4.04 -4.26

Competitive Comparison of Fresh Tracks Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Fresh Tracks Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresh Tracks Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's Beneish M-Score falls into.



Fresh Tracks Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Fresh Tracks Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.0774+0.528 * 1+0.404 * 0+0.892 * 1.1531+0.115 * 0.3564
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.672+4.679 * -0.174521-0.327 * 0.4771
=-4.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.05 Mil.
Revenue was 0 + 7.944 + 0.053 + 0.009 = $8.01 Mil.
Gross Profit was 0 + 7.944 + 0.053 + 0.009 = $8.01 Mil.
Total Current Assets was $11.55 Mil.
Total Assets was $11.59 Mil.
Property, Plant and Equipment(Net PPE) was $0.03 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.04 Mil.
Selling, General, & Admin. Expense(SGA) was $11.18 Mil.
Total Current Liabilities was $1.66 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -1.238 + 2.104 + -2.284 + -4.276 = $-5.69 Mil.
Non Operating Income was 0.414 + 0.107 + 0.082 + 0.068 = $0.67 Mil.
Cash Flow from Operations was -1.124 + 3.082 + -1.816 + -4.485 = $-4.34 Mil.
Total Receivables was $0.50 Mil.
Revenue was 2.05 + 0.486 + 4.315 + 0.092 = $6.94 Mil.
Gross Profit was 2.05 + 0.486 + 4.315 + 0.092 = $6.94 Mil.
Total Current Assets was $10.08 Mil.
Total Assets was $10.27 Mil.
Property, Plant and Equipment(Net PPE) was $0.12 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.03 Mil.
Selling, General, & Admin. Expense(SGA) was $14.43 Mil.
Total Current Liabilities was $3.08 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.045 / 8.006) / (0.504 / 6.943)
=0.005621 / 0.072591
=0.0774

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6.943 / 6.943) / (8.006 / 8.006)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11.552 + 0.034) / 11.586) / (1 - (10.083 + 0.124) / 10.271)
=0 / 0.006231
=0

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=8.006 / 6.943
=1.1531

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.03 / (0.03 + 0.124)) / (0.041 / (0.041 + 0.034))
=0.194805 / 0.546667
=0.3564

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(11.184 / 8.006) / (14.434 / 6.943)
=1.396952 / 2.078928
=0.672

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 1.656) / 11.586) / ((0 + 3.077) / 10.271)
=0.142931 / 0.299581
=0.4771

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-5.694 - 0.671 - -4.343) / 11.586
=-0.174521

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Fresh Tracks Therapeutics has a M-score of -4.26 suggests that the company is unlikely to be a manipulator.


Fresh Tracks Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh Tracks Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2000 Central Avenue, Suite 100, Boulder, CO, USA, 80301
Fresh Tracks Therapeutics Inc does not have any operations as it has discontinued its activities.
Executives
Monica E. Luchi officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy officer: General Counsel and CCO C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha officer: Chief Research & Dev. Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant director 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton officer: Chief Accounting Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown director, officer: Chief Executive Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer officer: COO and Secretary 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru director C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii officer: Chief Financial Officer
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja officer: Chief Medical Officer 121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy officer: Chief Business Officer C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju director 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers officer: Chief Financial Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301